

DLL3 (27-215)
Catalog # PVGS1833**Specification**

DLL3 (27-215) - Product Information

Primary Accession
Species
Human

[Q9NYJ7-1](#)

Sequence
Ala27-Glu215

Purity
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level
Less than 1EU per µg by the LAL method.

Biological Activity
Immobilized DLL3 (27-215), His&Flag, Human (Cat.No.: Z03950) at 0.2 µg/ml (100 µl/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag

Expression System
HEK293

Theoretical Molecular Weight
22.30 kDa

Formulation
Lyophilized from 0.22 µm filtered solution in PBS, 360mM NaCl, 200mM L-arginine (pH 8.0).

Reconstitution
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 µg/ml.

Storage & Stability
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

DLL3 (27-215) - Additional Information

Target Background
Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.

DLL3 (27-215) - Protein Information**DLL3 (27-215) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

DLL3 (27-215) - Images